Tvardi Therapeutics (TVRD) Competitors $33.88 -1.52 (-4.29%) As of 09/12/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TVRD vs. LENZ, GPCR, ZYME, STOK, UPB, SPRY, ORIC, SYRE, PHAR, and SIONShould you be buying Tvardi Therapeutics stock or one of its competitors? The main competitors of Tvardi Therapeutics include LENZ Therapeutics (LENZ), Structure Therapeutics (GPCR), Zymeworks (ZYME), Stoke Therapeutics (STOK), Upstream Bio (UPB), ARS Pharmaceuticals (SPRY), Oric Pharmaceuticals (ORIC), Spyre Therapeutics (SYRE), Pharming Group (PHAR), and Sionna Therapeutics (SION). These companies are all part of the "pharmaceutical products" industry. Tvardi Therapeutics vs. Its Competitors LENZ Therapeutics Structure Therapeutics Zymeworks Stoke Therapeutics Upstream Bio ARS Pharmaceuticals Oric Pharmaceuticals Spyre Therapeutics Pharming Group Sionna Therapeutics LENZ Therapeutics (NASDAQ:LENZ) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership. Do analysts rate LENZ or TVRD? LENZ Therapeutics presently has a consensus price target of $49.60, suggesting a potential upside of 20.01%. Tvardi Therapeutics has a consensus price target of $64.25, suggesting a potential upside of 89.64%. Given Tvardi Therapeutics' higher possible upside, analysts plainly believe Tvardi Therapeutics is more favorable than LENZ Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LENZ Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Tvardi Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to LENZ or TVRD? In the previous week, LENZ Therapeutics had 3 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 4 mentions for LENZ Therapeutics and 1 mentions for Tvardi Therapeutics. Tvardi Therapeutics' average media sentiment score of 1.89 beat LENZ Therapeutics' score of 1.57 indicating that Tvardi Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment LENZ Therapeutics Very Positive Tvardi Therapeutics Very Positive Do institutionals & insiders hold more shares of LENZ or TVRD? 54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are held by institutional investors. 6.9% of LENZ Therapeutics shares are held by company insiders. Comparatively, 3.1% of Tvardi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has stronger valuation & earnings, LENZ or TVRD? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLENZ TherapeuticsN/AN/A-$49.77M-$1.90-21.75Tvardi TherapeuticsN/AN/A-$70.87MN/AN/A Which has more risk & volatility, LENZ or TVRD? LENZ Therapeutics has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500. Comparatively, Tvardi Therapeutics has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Is LENZ or TVRD more profitable? LENZ Therapeutics has a net margin of 0.00% compared to Tvardi Therapeutics' net margin of -678.79%. LENZ Therapeutics' return on equity of -25.63% beat Tvardi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets LENZ TherapeuticsN/A -25.63% -24.43% Tvardi Therapeutics -678.79%-565.83%-66.71% SummaryLENZ Therapeutics beats Tvardi Therapeutics on 9 of the 11 factors compared between the two stocks. Get Tvardi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVRD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TVRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TVRD vs. The Competition Export to ExcelMetricTvardi TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$331.96M$3.20B$5.87B$10.13BDividend YieldN/A2.30%5.68%4.60%P/E RatioN/A21.1774.5225.93Price / SalesN/A436.80537.17192.28Price / CashN/A46.6837.5660.44Price / Book-11.229.6112.166.29Net Income-$70.87M-$53.29M$3.28B$270.77M7 Day Performance8.90%0.28%0.87%3.88%1 Month Performance42.71%5.73%4.96%4.88%1 Year PerformanceN/A10.52%60.74%26.01% Tvardi Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TVRDTvardi Therapeutics2.7188 of 5 stars$33.88-4.3%$64.25+89.6%N/A$331.96MN/A0.0080Positive NewsLENZLENZ Therapeutics1.6193 of 5 stars$41.98+5.2%$49.60+18.2%+100.1%$1.14BN/A-22.09110Positive NewsGPCRStructure Therapeutics3.3486 of 5 stars$22.08+11.7%$75.71+242.9%-48.1%$1.14BN/A-21.03136News CoveragePositive NewsAnalyst RevisionZYMEZymeworks2.3954 of 5 stars$15.05+6.9%$21.43+42.4%+29.2%$1.13B$122.87M-10.03460Positive NewsSTOKStoke Therapeutics3.9721 of 5 stars$20.68+5.3%$25.57+23.7%+71.1%$1.08B$36.56M24.33100Positive NewsUPBUpstream Bio1.9862 of 5 stars$19.97+1.5%$56.50+182.9%N/A$1.06B$2.37M0.0038Positive NewsSPRYARS Pharmaceuticals2.6568 of 5 stars$10.07-5.8%$32.50+222.7%-20.6%$1.06B$89.15M-20.5590Positive NewsORICOric Pharmaceuticals4.5439 of 5 stars$10.88+1.0%$17.29+58.9%+19.0%$1.05BN/A-5.7680Positive NewsSYRESpyre Therapeutics2.3307 of 5 stars$17.00+0.1%$53.40+214.1%-45.0%$1.03B$890K-5.0073Positive NewsPHARPharming Group2.0927 of 5 stars$15.13+1.7%$30.00+98.3%+95.1%$1.02B$297.20M-116.38280News CoverageShort Interest ↑SIONSionna Therapeutics2.8099 of 5 stars$24.00+4.1%$36.00+50.0%N/A$1.02BN/A0.0035 Related Companies and Tools Related Companies LENZ Therapeutics Alternatives Structure Therapeutics Alternatives Zymeworks Alternatives Stoke Therapeutics Alternatives Upstream Bio Alternatives ARS Pharmaceuticals Alternatives Oric Pharmaceuticals Alternatives Spyre Therapeutics Alternatives Pharming Group Alternatives Sionna Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TVRD) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tvardi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tvardi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TVRD Stock Alerts